CNS-Focused Rapport Therapeutics Preps IPO to Back Phase 2-Ready Epilepsy Drug
Rapport Therapeutics’ lead program could offer more targeted epilepsy treatment compared to currently available anti-seizure medications, which introduce many side effects. The IPO will support plans to develop the oral small molecule in focal epilepsy as well as peripheral neuropathic pain and bipolar disorder.